328 related articles for article (PubMed ID: 32912771)
1. Update on gastroenteropancreatic neuroendocrine tumors.
Andreasi V; Partelli S; Muffatti F; Manzoni MF; Capurso G; Falconi M
Dig Liver Dis; 2021 Feb; 53(2):171-182. PubMed ID: 32912771
[TBL] [Abstract][Full Text] [Related]
2. Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management.
Panzuto F; Massironi S; Partelli S; Campana D; Rinzivillo M; Invernizzi P; Andreasi V; Lamberti G; Falconi M
Surg Oncol; 2020 Dec; 35():141-148. PubMed ID: 32877883
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
4. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
[TBL] [Abstract][Full Text] [Related]
5. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].
Luley K; Gebauer J; Gebauer N; Tharun L; Buchmann I; Barkhausen J; von Bubnoff N; Lindner K; Keck T; Lehnert H; Schmid SM
Internist (Berl); 2020 Aug; 61(8):875-890. PubMed ID: 32676723
[TBL] [Abstract][Full Text] [Related]
6. How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.
Fermi F; Andreasi V; Muffatti F; Crippa S; Tamburrino D; Partelli S; Falconi M
Curr Oncol Rep; 2022 Feb; 24(2):227-239. PubMed ID: 35076884
[TBL] [Abstract][Full Text] [Related]
7. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Cloyd JM; Konda B; Shah MH; Pawlik TM
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
[TBL] [Abstract][Full Text] [Related]
9. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.
Desai GS; Pande P; Chhabra V; Shah RC; Jagannath P
Indian J Gastroenterol; 2019 Oct; 38(5):399-410. PubMed ID: 31802438
[TBL] [Abstract][Full Text] [Related]
10. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.
Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A
J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124
[TBL] [Abstract][Full Text] [Related]
11. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
Perez K; Chan J
Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
[TBL] [Abstract][Full Text] [Related]
13. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
Saleh M; Bhosale PR; Yano M; Itani M; Elsayes AK; Halperin D; Bergsland EK; Morani AC
Abdom Radiol (NY); 2022 Sep; 47(9):3078-3100. PubMed ID: 33095312
[TBL] [Abstract][Full Text] [Related]
14. [Consensus and controversy of endoscopic diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors].
Chen H; Chen Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):982-986. PubMed ID: 28900987
[TBL] [Abstract][Full Text] [Related]
15. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA
Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087
[TBL] [Abstract][Full Text] [Related]
16. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
17. [Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy].
Ye C; Yuan CH; Li G; Zheng L; Xiu DR
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):866-871. PubMed ID: 31694137
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
[TBL] [Abstract][Full Text] [Related]
19. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
20. [Gastroenteropancreatic neuroendocrine tumors : (GEP-NENs)].
Sebesta C; Feichter A; Selimi F
Wien Med Wochenschr; 2023 Jun; 173(9-10):221-226. PubMed ID: 36512264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
